30.03.2016

GSK Malta supports global health awareness campaign Healthy Lungs for Life

GSK Malta is supporting the European Respiratory Society (ERS) and the European Lung Foundation (ELF) as partners of the global health initiative, Healthy Lungs for Life (HLfL). The campaign seeks to reduce the number of people living with respiratory disease by raising awareness of lung conditions and ways to prevent lung damage.

HLfL highlights the importance of physical activity with its ‘Take the Active Option’ theme. This reflects the growing body of evidence supporting the importance of regular physical activity for lung health.1-5

To mark the change in season and in support of this year’s theme, GSK Malta is driving a better understanding and appreciation of lung health.

“The importance of healthy, active living should not be underestimated. Regular physical activity can improve quality of life and can reduce the risk of long-term lung diseases. GSK is proud to partner with the European Respiratory Society and European Lung Foundation on their campaign to support people to make positive changes to improve their symptoms, quality of life and reduce their long-term risk of living with asthma and COPD,” said Mario Sciberras, General Manager, GSK Malta.

Each year in the EU, one in eight of all deaths are due to respiratory diseases6 and the total cost, including the value of disability-adjusted life-years lost to respiratory disease is estimated at a minimum of €380 billion.7 It is estimated that around 235 million people in the world currently have asthma,8 and 329 million people are living with COPD.9 In Malta, asthma and COPD combined affect 13% of the population.10

“Respiratory diseases such as asthma and COPD can often be alleviated by building a small amount of physical activity into a daily routine. Small actions like these can make a substantial impact on respiratory health and help people overcome the daily challenges that they face living with respiratory disease,” said Mr Sciberras.

As leaders in respiratory, GSK is committed to improving the lives of those living with asthma, COPD and other related illnesses. Asthma and COPD combined have a huge economic, social and personal impact, yet much of this can be prevented.

Ends

About Healthy Lungs for Life

Healthy Lungs for Life is a global long-term health awareness campaign that aims to speak not only to those already affected by lung disease, in order to improve their quality of life, but also to those who may be affected in the future. It is one of the largest ever lung health campaigns, and is targeted at all stakeholders in the respiratory landscape: healthcare professionals, scientists, primary care, policy makers and the public. The objective is to focus on prevention and public education, to try and reduce the burden of lung disease on society.

The campaign has been created and led by the European Respiratory Society and the European Lung Foundation and is a partnership between organisations across the globe including patient advocacy organisations, professional bodies, pharmaceutical companies and academic institutions. It was launched on a European level at the ERS International Congress in September 2015.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

References

  1. Burtin C, et al. Effectiveness of exercise training in patients with COPD: The role of muscle fatigue. Eur Respir J. 2012;40:338-344.
  2. Grünig E, et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J. 2012;40:84-92.
  3. Dogra S, et al. Exercise is associated with improved asthma control in adults. Eur Respir J. 2011;37:318-323.
  4. Schneiderman JE, et al. Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis. Eur Respir J. 2014;43:817-823.
  5. Lannefors L, et al. Physical training: vital for survival and quality of life in cystic fibrosis. Breathe 2012;8:309-311.
  6. European Lung Foundation and European Respiratory Society. Lung health in Europe: Facts and Figures. 2013. Available at http://www.europeanlung.org/assets/files/publications/lung_health_in_europe_facts_and_figures_web.pdf [Last accessed: November 2015].
  7. European Respiratory Society. European Lung White Book. 2015. Available at: http://www.erswhitebook.org [Last accessed: November 2015].
  8. World Health Organization. Asthma Factsheet (online). 2013. Available at: http://www.who.int/mediacentre/factsheets/fs307/en/ [Last accessed: November 2015].
  9. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015. Available at: http://dx.doi.org/10.1016/S0140-6736(15)60692-4. [Last accessed: November 2015].
  10. Self-reported lifetime prevelance rate of Asthma and COPD. European Health Interview Survey. 2008.

MLT_GIB/RESP/0003/16
Date of preparation: 30/03/2016